Alasmi et al reported nomograms for predicting effects of clomiphene citrate therapy on males with abnormal semen parameters. The authors are from Prince Sattam bin Abdulaziz University (Saudi Arabia), Lunenfeld-Tanenbaum Research Institute (Toronto), Cleveland Clinic, and University of Toronto.
Patient selection: abnormal semen parameters, to be treated with clomiphene citrate
Parameters:
(1) age in years, from 22 to 50
(2) testosterone in nmol/L prior to therapy
(3) serum LH in IU/L prior to therapy
(4) serum FSH in IU/L prior to therapy
(5) semen volume in mL prior to therapy
(6) sperm motility in percent prior to therapy, from 0 to 80%
(7) sperm motility of 0%
(8) sperm concentration in millions per mL prior to therapy, from 0 to 10
(9) sperm concentration of 0
points for age from 22 to 38 years
= (0.0331 * ((age)^2)) - (3.023 * (age)) + 66.83
points for age from 38 to 50 years
= (0.02581 * ((age)^2)) - (1.587 * (age)) + 23.01
points for testosterone
= 1.32 * (testosterone)
points for LH =
= MAX(0,42.9 - (0.858 * (LH)))
points for FSH =
= 0.26 * (FSH)
points for semen volume =
= MAX(0,5.4 - (0.675 * (volume)))
points for sperm motility =
= (-0.0014 * ((motile)^2)) + (0.296 * (motile)) + 0.302
points for sperm concentration =
= MAX(0,100 - (10 * (sperm concentration)))
|
Parameter
|
Findings
|
Points
|
|
sperm motility 0%
|
true
|
0
|
|
|
false
|
14.7
|
|
sperm concentration 0
|
true
|
0
|
|
|
false
|
10.7
|
total score =
= SUM(points for all of the parameters)
Interpretation:
• minimum scoer: 0
• maximum score: 282.2
|
Score
|
Probability of Sperm Concentration = 0
|
|
0 to 149.5
|
< 0.2%
|
|
149.6 to 161.7
|
0.2 to 0.5%
|
|
161.8 to 165.6
|
0.5 to 1%
|
|
165.7 to 169.4
|
1 to 10%
|
|
> 169.4
|
> 10%
|
